Dr. John D. Minna is Director of the Hamon Center for Therapeutic Oncology Research at The University of Texas Southwestern Medical Center at Dallas (UTSW). He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. Minna has served on the Scientific Advisory Boards for several cancer centers, as well as for the National Cancer Institute and the Board of Directors for American Association for Cancer Research and American Society for Clinical Oncology. He received the Bristol Meyers Award for Lung Cancer Research, the Rosenthal Cancer Research Prize, the Alton Ochsner Award Relating Smoking and Disease in 2004, the American Society of Clinical Oncology Lifetime Scientific Achievement Award in 2005 and the ASCO Statesman Award in 2007. As part of this, he has led a joint Lung Cancer NCI SPORE grant between UTSW and the MD Anderson Cancer Center. He also directs a NASA Special Program of Research Excellence to study the effects of high-energy particle radiation and low-dose gamma radiation on lung carcinogenesis.
His work has focused on understanding the molecular pathogenesis of lung cancer and translating this into the clinic and developing personalized medicine for lung cancer. Dr. Minna is part of the NCI Cancer Target Discovery and Development Network and several State of Texas Cancer Prevention and Research Institute grants to discover new therapeutic targets in lung cancer including manipulation of nuclear hormone receptors. He heads the Molecular Therapeutics of Cancer Program for the UTSW Simmons Cancer Center. He is trying to discover the molecular signatures in lung cancer predictive of response to therapy, as well as how to target this therapy, and using a new model system of immortalized human bronchial epithelial cells to dissect the steps in lung cancer pathogenesis.
Dr. Minna graduated from Stanford University School of Medicine, was a resident in medicine at Massachusetts General Hospital, a Research Associate at the National Institutes of Health, Chief of the Section of Somatic Cell Genetics and then Chief of the NCI-VA and NCI-Navy Medical Oncology Branches at the National Cancer Institute. From 1991 until the present, he has been a Professor of Internal Medicine and Pharmacology and Director of the Hamon Center for Therapeutic Oncology Research at UTSW.
Mailing List
